The year-long study was an extension of the original study that resulted in the drug’s approval in Oct. 2010. Researchers looked at 67 previously treated patients and 47 patients who switched from placebo therapy. At the end of the trail, slightly more than half the patients were completely abstinent from opioid use.
Related Articles on Opioids:
7 Trends Affecting the Future of Pain Management in Surgery Centers
American Pain Society Supports CDC’s Attention to Prescription Drug Misuse
Nano-formulated NSAIDs Provide Relief at Lower Doses
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.